Dec 21, 2023, 01:00 AM by User Not Found

Bio-IT World | In a turnaround of the usual metabolomics study approach, University of California San Diego scientists are homing in on the microbial-produced molecules that interact with cells and affect human health. A couple million such molecules are likely awaiting discovery in this fashion.

Dec 20, 2023, 09:15 AM by

Terran Biosciences Receives FDA Clearance for NM-101, the Industry’s First Software for the Analysis of Neuromelanin-sensitive MRI

Dec 20, 2023, 09:15 AM by

Owkin, a French-American biotechnology company that applies artificial intelligence (AI) to drug discovery, development, and diagnostics, today announced that it has entered into a collaboration agreement with MSD, the trade name of Merck & Co Inc., Rahway NJ USA to develop and commercialize AI-powered digital pathology diagnostics for the EU market.

Dec 20, 2023, 09:15 AM by

AppOmni, SaaS Security Posture Management (SSPM) leader and SaaS security pioneer, today unveiled a groundbreaking advancement with the introduction of AskOmni. This first AI-powered SSPM assistant developed by the AppOmni OmniScience team propels SSPM into new dimensions, simplifying security operations and issue remediation, and helping organizations secure mission-critical SaaS environments.

Dec 20, 2023, 09:15 AM by

Dec 20, 2023, 09:15 AM by

Dec 20, 2023, 09:15 AM by

Abzena, a leading CDMO for biologics, collaborates with the FDA on a publication endorsing the MHC Associated Peptide Proteomics (MAPPs) assay for assessing immunogenicity in drug development. The article underscores MAPPs' precision in identifying potential immunogenicity risks in early preclinical stages, reducing the likelihood of anti-drug antibodies (ADAs) and optimizing biologics. Abzena integrates MAPPs into its immunogenicity services, aiming to de-risk drug development. The Chief Scientific Officer, Dr. Campbell Bunce, emphasizes the assay's value in informing drug regions that may induce ADAs. The collaboration aims to expedite safer, more effective therapies for patients.

Dec 20, 2023, 01:00 AM by User Not Found

Bio-IT World | Driven by advancements in technology and data accessibility, computational methods and artificial intelligence (AI) have seen remarkable growth this past decade. This surge has ushered in a new era of problem-solving across a plethora of industries and domains.

Dec 19, 2023, 09:29 AM by

Hi Hope you are well and are having a great week so far! I just wanted to pass on the latest news from Recipharm, who has chosen Veeva Systems to streamline global quality operations. The move aims to enhance oversight, resource efficiency, validation speed, and inspection readiness. The full release is below. Thank you Charlotte

Dec 19, 2023, 09:29 AM by

PubHive Navigator Enterprise Portal consolidates all workspaces, virtual libraries, folders, and internal content into one intuitive research platform, streamlining tailored research workflow and collaboration.

Dec 19, 2023, 01:00 AM by User Not Found

Bio-IT World | Driven by advancements in technology and data accessibility, computational methods and artificial intelligence (AI) have seen remarkable growth this past decade. This surge has ushered in a new era of problem-solving across a plethora of industries and domains.

Dec 18, 2023, 08:49 AM by

Dec 18, 2023, 08:49 AM by

Dec 18, 2023, 08:49 AM by

Dec 18, 2023, 08:49 AM by

Oz-UK Ltd announces the installation of its new low-GWP (global warming potential) manufacturing line.

Dec 18, 2023, 08:49 AM by

Leading computational biology company PrecisionLife®, which is driving precision medicine in complex chronic diseases, the ME/CFS charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh have been awarded a £622,000 grant by Innovate UK's Advancing Precision Medicine programme to improve diagnosis and treatment for the millions of people affected by ME/CFS and long Covid.

Dec 17, 2023, 19:03 PM by User Not Found

Bio-IT World | On Sunday, Illumina announced that the company will divest GRAIL.

Dec 15, 2023, 09:46 AM by

Vergent Bioscience has enrolled the first patients in a Phase 2, multi-center study evaluating the efficacy and safety of VGT-309 in patients with cancer in the lung. Researchers at six sites in the U.S. and Australia will investigate the agent’s ability to help surgeons see tumors in real time during minimally invasive and robotic-assisted surgical procedures.

Dec 15, 2023, 09:46 AM by

I just wanted to follow up to see if you had received my initial email regarding ReciBioPharm partners with Acuitas Therapeutics? Please let me know if there is any further information you require from me for this.

Dec 15, 2023, 09:46 AM by

Medical and consumer genetics testing innovator and Imperial College London spin-out, DnaNudge, today announces that it has received approval from Ghana’s Food and Drugs Authority (FDA) to deliver its breakthrough four-in-one, respiratory viruses test for clinical deployment both inside and outside labs in the West African country.